Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed enzymes that ligate amino acids onto tRNA molecules. Genes encoding ARSs have been implicated in myriad dominant and recessive disease phenotypes. Glycyl-tRNA synthetase (GARS) is a bifunctional ARS that charges tRNA Gly in the cytoplasm and mitochondria. GARS variants have been associated with dominant Charcot-Marie-Tooth disease but have not been convincingly implicated in recessive phenotypes. Here, we describe a patient from the NIH Undiagnosed Diseases Program with a multisystem, developmental phenotype. Whole-exome sequence analysis revealed that the patient is compound heterozygous for one frameshift (p.Glu83Ilefs*6) and one missense (p.Arg310Gln) GARS variant. Using in vitro and in vivo functional studies, we show that both GARS variants cause a loss-of-function effect: the frameshift variant results in depleted protein levels and the missense variant reduces GARS tRNA charging activity. In support of GARS variant pathogenicity, our patient shows striking phenotypic overlap with other patients having ARS-related recessive diseases, including features associated with variants in both cytoplasmic and mitochondrial ARSs; this observation is consistent with the essential function of GARS in both cellular locations. In summary, our clinical, genetic, and functional analyses expand the phenotypic spectrum associated with GARS variants.
INTRODUCTION
Aminoacyl-tRNA synthetases (ARS) are ubiquitously expressed, essential enzymes that charge tRNA molecules with cognate amino acidsthe first step of cytoplasmic and mitochondrial protein synthesis. The human nuclear genome harbors 37 ARS genes including 17 that encode a cytoplasmic enzyme, 17 that encode a mitochondrial enzyme, and three that encode bifunctional enzymes that charge tRNA for protein synthesis in both cellular locations (Antonellis & Green, 2008) .
ARS loci and enzymes are named by the single-letter code for the amino acid that they charge, plus "ARS" and a variable "2" for enzymes that charge tRNA exclusively in the mitochondria. For example, AARS encodes cytoplasmic alanyl-tRNA synthetase and AARS2 encodes the mitochondrial form of alanyl-tRNA synthetase.
Glycyl-tRNA synthetase (GARS; MIM# 600287) encodes a bifunctional tRNA-charging enzyme that differentially localizes to the cytoplasm or mitochondria via two translation start sites that either include or exclude a mitochondrial targeting sequence (Antonellis & Green, 2008) . GARS variants have been implicated in CMT2D, an autosomal-dominant, axonal form of Charcot-Marie-Tooth disease (MIM# 600287) (Antonellis et al., 2003) . CMT2D is characterized by an upper limb predominant peripheral neuropathy that affects motor and sensory function in the distal extremities (Sivakumar et al., 2005) .
One patient with a recessive mitochondrial phenotype was reported to Human Mutation. 2017;38:1412-1420.
c 2017 Wiley Periodicals, Inc. 1412 wileyonlinelibrary.com/journal/humu be compound heterozygous for GARS missense variants: p.Arg596Gln and p.Ser635Leu (McMillan et al., 2014) . However, certain limitations of the above study indicated that additional analyses were required to determine the role of GARS variants in recessive disease. First, the restriction of the phenotype to impaired mitochondrial function is surprising given the role of GARS in cytoplasmic protein translation and the severity of fly and mouse phenotypes associated with biallelic mutations in GARS (Chihara, Luginbuhl, & Luo, 2007; Motley et al., 2011) . Second, the authors of the above study did not provide functional data supporting the pathogenicity of the variants; enzyme kinetic analyses were not performed and, indeed, p.Ser635Leu was previously shown to encode a functional GARS enzyme (Nangle, Zhang, Xie, Yang, & Schimmel, 2007) . Finally, p.Ser635Leu was previously shown to not be associated with dominant human disease (Griffin et al., 2014) ; however, the variant was not evaluated for a role in recessive phenotypes. Here, we present clinical, genetic, and functional data that implicate compound heterozygosity for loss-of-function GARS variants in a recessive, early onset, multisystem, developmental phenotype. Our findings expand the phenotypic heterogeneity associated with GARS variants. Board (IRB). Clinical data were obtained after written informed consent from the proband's parents. Genomic DNA was extracted from whole blood using the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany). Single-nucleotide polymorphism (SNP) analyses were performed using an Illumina Omni Express 12 (hg18) SNP array and the Genome Studio software program. Whole-exome sequencing was performed using the Illumina HiSeq2000 platform and the TrueSeq capture kit (Illumina, San Diego, CA) by the NIH Intramural Sequencing Center (NISC) as described (Bentley et al., 2008; Gahl et al., 2012; Gnirke et al., 2009; Teer et al., 2010) . Sequence data were aligned to the human reference genome (hg19) using Novoalign (Novocraft Technologies, Petaling Jaya, Selangor, Malaysia). Variants were analyzed, sorted, and filtered with VarSifter and a graphical java tool to view, sort, and filter variants (Teer, Green, Mullikin, & Biesecker, 2012) . Variants were filtered based on allele frequencies in the NIH-UDP (Gahl & Tifft, 2011; Gahl et al., 2012; Markello et al., 2012) 
MATERIAL AND METHODS

Clinical evaluation and variant analysis
Protein isolation and western blot analysis
Primary fibroblasts from the affected individual and a control individual (i.e., bearing no GARS variants) were obtained and utilized for western blot analysis. Cells were cultured in T-75cm 3 -treated cell culture flasks (USA Scientific, Ocala, FL) and maintained at 37 • C and 5% and 50 g/ml streptomycin; ThermoFisher Scientific]). Cells were harvested at 90% confluence with 3 ml .25% trypsin (ThermoFisher Scientific), quenched with 7 ml complete cell medium, and collected at 2,000 rpm for 2 min. The resulting pellet was resuspended in 1 ml cell lysis buffer (RIPA buffer [ThermoFisher Scientific] + 1× EDTAfree protease inhibitor [ThermoFisher Scientific]) and incubated at 4 • C for 30 min with gentle shaking. Cell debris was collected at 4 • C and 12,000 rpm for 5 min, and the resulting supernatant was subjected to western blot analysis.
Total protein concentration was measured using the Thermo Scientific Pierce BCA Protein Assay Kit (ThermoFisher Scientific), and 10 g protein/sample was analyzed unless otherwise specified. Protein samples were prepared in 1× SDS-sample buffer (ThermoFisher Scientific) and 1 l 2-mercaptoethanol ( ME), denatured at 99 • C for 5 min and separated on a precast 4%-20% tris-glycine protein gel (ThermoFisher Scientific) at 150 V for 2 hr at room temperature.
Prior to protein transfer, a polyvinylidene difluoride (PVDF) membrane was prewashed in 100% methanol and soaked in 1× transfer buffer (ThermoFisher Scientific) with extra thick blot paper (BioRad, Hercules, CA) and 3 mm chromatography paper (Whatman PLC, Maidstone, United Kingdom). Protein was transferred onto the membrane using a Transbot-SD Semi-Dry Transfer Cell (Bio-Rad) at 23V for 1.5 hr at room temperature and subsequently blocked over night at 4 • C in blocking solution (1 g dry milk powder, 50 ml 1× TBST [tris-buffered saline solution and tween 20, pH 7.5]). The membrane was cut in half and incubated in blocking solution with either anti-GARS 673 antibody (Antonellis et al., 2006) (at 1/2,000 dilution) or antiactin antibody (at 1/5,000 dilution [Sigma-Aldrich, St. Louis, MO]) at room temperature for 1 hr. The membrane was washed three times in 1× TBST to remove unbound primary antibody and incubated in blocking solution with 10 ng/ml donkey anti-rabbit IgG HRP secondary antibody (ThermoFisher Scientific) at room temperature for 1 hr. The membrane was washed three times in 1× TBST to remove unbound secondary antibody and exposed using SuperSignal West Dura substrate and enhancer (ThermoFisher Scientific). Western blot analysis was repeated four independent times with independent fibroblast cell lysates and ImageJ (https://imagej.nih.gov/ij/) was used to quantify band intensity. The analyzed control and affected fibroblast cell lines were passage-matched (±3 passages).
Generation of GARS expression constructs
GARS expression constructs were generated using Gateway cloning technology (Invitrogen). The human GARS open-reading frame was amplified from human cDNA using primers designed with Gateway sequences attB1 (forward) and attB2 (reverse; primer sequences available on request). Entry clones were generated by recombining PCR-purified amplicons into the pDONR221 vector using BP clonase.
After transformation into E. coli, DNA from individual entry clones was isolated and subjected to Sanger sequencing analysis to confirm the presence of the appropriate wild-type gene. Oligonucleotidescontaining sequences corresponding to the c.929G>A GARS variant (encoding p.Arg310Gln) were generated and mutagenesis was performed using the QuickChange II XL Site-Directed Mutagenesis Kit Stratagene (San Diego, CA). After transformation into E. coli, DNA from individual clones was purified and sequenced to confirm the presence of each variant and the absence of any errors. Validated entry clones were purified and recombined into a Gateway-compatible pET-21a(+) vector for aminoacylation assays (Griffin et al., 2014 ) using LR clonase. DNA from the resulting expression constructs was purified and digested with BsrGI New England Biosystems (Waltham, MA) to confirm the presence of the insert.
For yeast complementation assays, human GARS proteins were expressed from the pYY1 expression construct containing full-length, ΔMTS, or ΔMTSΔWHEP GARS, or no insert (empty); these constructs were a gift from Chin-I Chien and Chien-Chia Wang (National Central University, Taiwan) (Chien et al., 2014) . We made pYY1 Gatewaycompatible by digesting the empty pYY1 plasmid with SpeI (New Eng- 
Aminoacylation assays
Wild-type and p.Arg310Gln GARS were expressed in E. coli with a Cterminal His tag and purified with nickel affinity resins (Novagen, Billerica, MA). The T7 transcript of human tRNAGly/UCU (UCU, anticodon) was prepared and purified as previously described (Hou, Westhof, & Giegé, 1993) , heat denatured at 85 • C for 3 min, and annealed at 37 • C for 20 min before use. Steady-state aminoacylation assays were monitored at 37 • C in 50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 3H-glycine (Perkin Elmer, Waltham, MA) at a specific activity of 16,500 dpm/pmole. The reaction was initiated by mixing GARS enzyme (20-600 nM) with varying concentrations of tRNA (0.3-20 M). Aliquots of a reaction mixture were spotted on filter paper, quenched by 5% trichloroacetic acid, washed, dried, and measured for radioactivity using a liquid scintillation counter (LS6000SC; Beckman Coulter Inc, Pasadena, CA).
The amount of radioactivity retained on filter pads was corrected for quenching effects to determine the amount of synthesis of GlytRNAGly. Steady-state kinetics was determined by fitting the initial rate of aminoacylation as a function of tRNA concentration to the Michaelis-Menten equation (Schreier & Schimmel, 1972) .
Yeast complementation assays
Yeast complementation assays were carried out using the haploid S. cerevisiae strain disrupted for the endogenous GRS1 and maintained viable via pRS316 bearing wild-type GRS1 (Turner, Lovato, & Schimmel, 2000) . To assess the ability of wild-type and mutant human GARS alleles to support cellular growth, the haploid yeast strain was transformed with wild-type full-length, wild-type ΔMTS, or wild-type ΔMTSΔWHEP GARS, the corresponding p.Arg310Gln GARS expression constructs, or empty pYY1 (i.e., bearing no GARS insert) (Chien et al., 2014) . Transformed yeast cells were selected for the presence of pYY1 by growth on solid media lacking leucine (pYY1 harbors the LEU2 gene) and uracil (pRS316 harbors the URA3 gene). Colonies were grown to saturation in 2 ml liquid medium lacking leucine and uracil (-leu-ura) at 30 • C and shaking at 275 rpm for 48 hr. Each 2 ml saturated culture was spun down at 1,000 rpm and resuspended in 100 l UltraPure Rnase/DNase-free water. Undiluted cultures and dilutions of 1:10, 1:100, and 1:1,000 were spotted on 0.1% 5-FOA complete solid medium (Teknova, Hollister, CA) to select for cells that spontaneously lost the URA3-bearing maintenance vector (Boeke, LaCroute, & Fink, 1984) . Yeast viability was visually assessed after 4 days of incubation at 30 • C. Two colonies per transformation were assayed and each transformation was repeated twice.
RESULTS
Clinical and genetic analysis of patient UDP5316
A simplex pedigree was presented to the NIH Undiagnosed Diseases
Program. The proband is a 7-year-old Caucasian female of nonconsanguineous German and Polish ancestry with extreme growth retardation and multiple organ involvement as described below. She was a 1.52-kg infant born at 36 weeks gestation to a 27-year-old G1P0 mother by scheduled Caesarian section due to severe intrauterine growth retardation beginning at 29 weeks. There were no maternal exposures and maternal weight gain was only 5 pounds. APGAR scores were 4 and 9 at 1 and 4 min, respectively. Length, weight, and head circumference were all 50 th percentile for 31 weeks gestation. She remained in the NICU for 2 weeks for poor weight gain. Despite adequate calories, the child failed to thrive. X-rays at 7 months of age showed cephalofacial disproportion with a large calvaria, numerous wormian bones, and low-normal bone mineralization. Skull X-ray at 2 years 9 months of age no longer showed the wormian bones, but the rest of the findings remained the same (Supp. Fig. S1 ). Brain MRI at 29 months showed moderate-to-severe thinning of the corpus callosum, mild atrophy of the cerebellar vermis, and a small brain stem (Fig. 1A) . There was decreased cerebral white matter volume consistent with delayed myelination (also observed at 11 months of age; data not shown), and mildly enlarged ventricles. Cervical X-ray revealed that C5 through C7 were fused (Fig. 1B) . Cardiac evaluation at 4 years identified a moderately sized To identify candidate variants for the unexplained phenotype, whole-exome sequencing analysis was performed on genomic DNA isolated from the patient (UDP5316), her unaffected mother (UDP6340), and her unaffected father (UDP6341) (Fig. 2A) . cause an early frameshift variant p.Glu83Ilefs*6; and (2) c.929G>A, which is predicted to cause a missense variant p.Arg310Gln (Table 1) .
The unaffected mother carries p.Glu83Ilefs*6 in the heterozygous state, the unaffected father carries p.Arg310Gln in the heterozygous state, and the affected proband is compound heterozygous for both GARS variants ( Fig. 2A and B) . Neither variant is present in the ExAC/gnomAD database (Table 1 ) (Lek et al., 2016) . Modeling each of the identified GARS variants on the primary structure of the protein revealed that p.Glu83Ilefs*6 is predicted to ablate all key functional domains of the enzyme (both catalytic domains and the tRNA-binding domain) and that p.Arg310Gln affects a residue in the catalytic core of the enzyme (Fig. 2C) . Multiple-species conservation analysis revealed that p.Arg310Gln affects a residue that is conserved among diverse species including human, mouse, zebrafish, and worm (Fig. 2D ).
p.Glu83Ilefs*6 GARS reduces expression of the full-length GARS protein
Because p.Gly83IllefsX6 GARS encodes a premature stop codon, the variant is predicted to ablate the expression of full-length GARS, which would result in a 50% decrease in full-length GARS protein levels in patient cells. To test this, we performed western blot analysis using whole-cell lysates from fibroblasts isolated from patient UDP5316 and . Before inoculating on medium containing 5-FOA, each strain was diluted 1:10, 1:100, or 1:1,000 in water. Please note the minimal growth associated with the wild-type full-length protein in the undiluted sample, the intermediate growth associated with the wild-type Δ protein in the undiluted and 1:10 diluted samples, and the robust growth associated with wild-type ΔΔ protein in all dilutions from an unaffected control (i.e., a patient negative for GARS variants).
TA B L E 1 GARS variants identified in patient UDP5316
Protein samples were electrophoresed, transferred onto a PVDF membrane, and incubated with an anti-GARS antibody (Antonellis et al., 2006) . Our results revealed a ∼50% reduction in full-length GARS protein levels in the patient fibroblast cells compared with the control cell line (Fig. 2A) ; a similar assessment of three additional control fibroblast samples confirmed these findings (Supp. Fig. S2 ). To confirm the sensitivity of our western blot analysis, we analyzed 20, 10, and 5 g of total protein from the control cell lysate with the same antibody and were able to detect a 50% reduction in protein levels (Fig. 3A) . We therefore conclude that p.Gly83IllefsX6 GARS ablates the expression of fulllength GARS and posit that the remaining protein represents translation from the p.Arg310Gln GARS allele.
The p.Arg310Gln GARS variant reduces enzyme activity
The primary function of GARS is to charge tRNA Gly molecules with glycine in a two-step aminoacylation reaction: (1) binding and activation of the amino acid with ATP and (2) conjugation of the activated amino acid to the 3'-end of the appropriate tRNA (Delarue, 1995) . The aminoacylation assay evaluates the completion of both steps and has been used to establish that CMT2D-associated variants disrupt GARS enzymatic activity (Griffin et al., 2014; Nangle et al., 2007) . We assessed recombinant human GARS proteins (wild type and p.Arg310Gln) for the ability to charge human cytoplasmic tRNA Gly with tritium-labeled glycine as previously described (Griffin et al., 2014) . Analysis of the initial rate of aminoacylation as a function of the tRNA substrate concentration showed that p.Arg310Gln
GARS demonstrates less than 1% aminoacylation activity compared with wild-type GARS ( Fig. 3B ; Table 2) indicating that it is a hypomorphic allele.
The p.Arg310Gln GARS variant does not support yeast cell growth in complementation assays
Yeast complementation assays have been employed to reveal lossof-function characteristics of CMT2D-associated GARS variants (Antonellis et al., 2006; Griffin et al., 2014) . While previous efforts employed the yeast ortholog of GARS (GRS1) to assess human variants (Antonellis et al., 2006; Griffin et al., 2014; Turner et al., 2000) , a recent study showed that three engineered isoforms of the human GARS protein were able to rescue deletion of GRS1: (1) full-length GARS allowed minimal cell growth; (2) GARS with the mitochondrial targeting (3) GARS with both the MTS and WHEP domain deleted (ΔMTSΔWHEP) allowed robust cell growth (Chien et al., 2014) (the function of the WHEP domain has not been defined but it is not essential for enzyme activity [Chang, Chien, Chang, Lin, & Wang, 2016] ). We therefore evaluated the effect of the p.Arg310Gln GARS variant in all three of the above GARS isoforms. Briefly, the wild-type or p.Arg310Gln
GARS open-reading frames (full-length, ΔMTS, or ΔMTSΔWHEP)
were cloned downstream of the yeast ADH1 promoter (Chien et al., 2014) , and yeast complementation assays were performed using a haploid yeast strain deleted for the endogenous GRS1 locus (ΔGRS1);
this strain carries wild-type GRS1 on a URA3-bearing maintenance vector to maintain viability (Turner et al., 2000) . Wild-type or mutant GARS expression constructs, or one with no GARS insert ("Empty"
in Fig. 3C ), were introduced into the above strain, and growth was subsequently evaluated on medium containing 0.1% 5-FOA, which selects for the spontaneous loss of the maintenance vector (Boeke et al., 1984) . All of the wild-type human GARS expression constructs supported yeast growth, whereas the empty plasmid did not (Fig. 3C) , consistent with human GARS supporting loss of the endogenous GRS1 locus and with GRS1 being an essential gene. In contrast, none of the p.Arg310Gln GARS expression constructs supported yeast cell growth, consistent with this being a loss-of-function allele (Fig. 3C ). Combined, our functional studies indicate that p.Gly83IllefsX6 GARS represents a null allele and that p.Arg310Gln GARS represents a hypomorphic allele.
DISCUSSION
Twenty-eight ARS loci encoding mitochondrial, cytoplasmic, and bifunctional ARS enzymes have been implicated in myriad dominant and recessive human diseases (Oprescu, Griffin, Beg, & Antonellis, 2017 Loss-of-function missense variants in GARS have been associated with CMT2D, which is characterized by distal muscle weakness and sensory loss that is predominant in the upper extremities (Antonellis et al., 2003; Sivakumar et al., 2005) . Interestingly, neither parent of the affected proband currently displays signs of CMT2D; EMG and nerve conduction studies performed on both parents were unremarkable at ages 30 (mother) and 32 (father); these ages are well beyond the average age of onset for CMT2D, which is typically in the second decade of life (Sivakumar et al., 2005) . With regard to the mother who carries the null allele (p.Gly83IllefsX6), this is perhaps not surprising since haploinsufficiency is not a likely mechanism of GARS-associated CMT2D; mice heterozygous for a null allele have no detectable phenotype, whereas mice heterozygous for a missense variant present with a dominant neuropathy (Motley et al., 2011; Seburn, Nangle, Cox, Schimmel, & Burgess, 2006) . In contrast, p.Arg310Gln GARS shows features of CMT2D-associated variants (Griffin et al., 2014) ; it is a missense variant in the catalytic domain that affects tRNA-charging capacity.
Two possible explanations for this discrepancy are the reduced penetrance of GARS variants as seen for p.Glu71Gly and p.Leu129Pro GARS (Sivakumar et al., 2005) and the poorly defined mechanism of CMT2D (i.e., p.Arg310Gln GARS may be a loss-of-function missense variant that is not dominantly toxic to peripheral nerve axons). Addressing this discrepancy will require animal models and molecular studies to determine whether, for example, p.Arg310Gln GARS inappropriately binds neuropilin-1, which has been observed for certain CMT2D-causing variants (He et al., 2015) .
In conclusion, we present clinical, genetic, and functional data that associate GARS variants with a severe, multisystem, developmental phenotype. This report exemplifies the growing number of ARS loci and alleles implicated in recessive human diseases , expands the phenotypic heterogeneity associated with GARS variants, and underscores the importance of employing careful clinical comparisons and informative functional studies to support the pathogenicity of newly identified ARS variants.
